The aim of this pilot study for the NorCAPITAL trial is to investigate the feasibility and safety of the drug clonidine in adolescent chronic fatigue syndrome (CFS). Specifically, the investigators wanted to assess appropriate dosage in relation to a) plasma concentration levels of clonidine, b) orthostatic cardiovascular responses (the pulse and blood pressure responses when rising up), and c) reports of possible adverse effects. A possible beneficial effect of clonidine in adolescent CFS will be investigated in NorCAPITAL, which is a randomized, placebo-controlled, double blind trial.
Study Type
INTERVENTIONAL
Allocation
NA
Masking
NONE
Enrollment
5
50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
Oslo University Hospital Rikshospitalet, Dept. of Pediatrics
Oslo, Norway
Plasma concentration level (Cmax and Co) of clonidine
Time frame: After 14 days of treatment
Orthostatic cardiovascular responses (head-up tilt test)
Time frame: After 14 days of treatment
Reports of adverse effects
Time frame: Participants will be followed for the duration of treatment period, an expected average of 14 days
Plasma concentration (Cmax) of clonidine
Time frame: First day of treatment, approximately 5 hours after the first dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.